Literature DB >> 12610014

Prospective analysis of mortality, morbidity, and risk factors in elderly diabetic subjects: Nagano study.

Masafumi Katakura1, Motoji Naka, Teruki Kondo, Nakako Nishii, Mitsuhisa Komatsu, Yoshihiko Sato, Keishi Yamauchi, Kunihide Hiramatsu, Mitsuru Ikeda, Toru Aizawa, Kiyoshi Hashizume.   

Abstract

OBJECTIVE: To clarify mortality and morbidity of intensively managed elderly diabetic individuals and to explore factors predicting mortality and diabetes-related end points. RESEARCH DESIGN AND METHODS: A total of 390 elderly (>or=65 years of age) outpatients with type 2 diabetes ( 173 men and 217 women, mean age 73.0 years) were analyzed. The mean HbA(1c) upon entry was 6.8% (332 receiving oral hypoglycemics and/or insulin) and blood pressure upon entry was 136/74 mmHg (219 receiving antihypertensive drugs). The patients have been followed-up for 3 years with HbA(1c) <7.0% and blood pressure <145/80 mmHg as targets, with mortality and an aggregate of fatal and nonfatal diabetes-related events as end points. Mortality rate and causes of mortality, as well as risk factors for mortality and morbidity, were determined.
RESULTS: The mortality rate, 2.9% per year, was comparable to that of the age- and sex-matched general population. Stroke was a leading cause of mortality after malignancy. By the univariate Cox proportional hazards model, only high serum creatinine and prior stroke were highly significant and strong risks for both end points. In those without prior stroke and receiving antihypertensive agents, the incidence of the diabetes-related end point based on their systolic blood pressure (SBP) quartile was U-shaped, with the nadir at the 3rd (SBP, 137-147 mmHg) and the peak at the 1st (SBP <or= 125 mmHg) quartile.
CONCLUSIONS: In well-controlled elderly diabetic subjects, there was no excessive mortality compared to the age- and sex-matched general population. Renal dysfunction and prior stroke were independent risks for mortality and morbidity. In those without prior stroke, a risk of too much lowering of blood pressure was suggested.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12610014     DOI: 10.2337/diacare.26.3.638

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  12 in total

Review 1.  Diabetes and stroke: part one--risk factors and pathophysiology.

Authors:  Bantwal Suresh Baliga; Jesse Weinberger
Journal:  Curr Cardiol Rep       Date:  2006-02       Impact factor: 2.931

2.  Traditional risk factors alone could not explain the excess mortality in patients with diabetes: a national cohort study of older Spanish adults.

Authors:  Enrique Regidor; Josep Franch; Mateu Seguí; Rosario Serrano; Fernando Rodríguez-Artalejo; Sara Artola
Journal:  Diabetes Care       Date:  2012-08-08       Impact factor: 19.112

3.  Glycemic control, complications, and death in older diabetic patients: the diabetes and aging study.

Authors:  Elbert S Huang; Jennifer Y Liu; Howard H Moffet; Priya M John; Andrew J Karter
Journal:  Diabetes Care       Date:  2011-04-19       Impact factor: 19.112

4.  Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial.

Authors:  Michael E Miller; Jeff D Williamson; Hertzel C Gerstein; Robert P Byington; William C Cushman; Henry N Ginsberg; Walter T Ambrosius; Laura Lovato; William B Applegate
Journal:  Diabetes Care       Date:  2013-10-29       Impact factor: 19.112

5.  Coronary heart disease incidence and mortality, and all-cause mortality among diabetic and non-diabetic people according to their smoking behavior in Finland.

Authors:  Noël C Barengo; Yvonne Teuschl; Vladislav Moltchanov; Tiina Laatikainen; Pekka Jousilahti; Jaakko Tuomilehto
Journal:  Tob Induc Dis       Date:  2017-02-02       Impact factor: 2.600

6.  Efficacy and safety of sitagliptin as compared with glimepiride in Japanese patients with type 2 diabetes mellitus aged ≥ 60 years (START-J trial).

Authors:  Yasuo Terauchi; Yuichiro Yamada; Hitoshi Ishida; Mitsuru Ohsugi; Masafumi Kitaoka; Jo Satoh; Daisuke Yabe; Nobuyuki Shihara; Yutaka Seino
Journal:  Diabetes Obes Metab       Date:  2017-04-12       Impact factor: 6.577

7.  Incidence rate and patient characteristics of severe hypoglycemia in treated type 2 diabetes mellitus patients in Japan: Retrospective Diagnosis Procedure Combination database analysis.

Authors:  Yuika Ikeda; Takekazu Kubo; Eisei Oda; Machiko Abe; Shigeru Tokita
Journal:  J Diabetes Investig       Date:  2018-01-16       Impact factor: 4.232

8.  A form of the metabolic syndrome associated with mutations in DYRK1B.

Authors:  Ali R Keramati; Mohsen Fathzadeh; Gwang-Woong Go; Rajvir Singh; Murim Choi; Saeed Faramarzi; Shrikant Mane; Mohammad Kasaei; Kazem Sarajzadeh-Fard; John Hwa; Kenneth K Kidd; Mohammad A Babaee Bigi; Reza Malekzadeh; Adallat Hosseinian; Masoud Babaei; Richard P Lifton; Arya Mani
Journal:  N Engl J Med       Date:  2014-05-15       Impact factor: 176.079

9.  Age-specific effectiveness and safety of newly initiated insulin therapy in Japanese patients with uncontrolled diabetes.

Authors:  Takayoshi Shiga; Hirohide Yokokawa; Yoshinobu Taneda; Eiichiro Sugihara; Mayumi Meijyo; Kazunori Mitsuhashi; Teruhiko Hisaoka; Hiroshi Isonuma
Journal:  Diabetes Ther       Date:  2013-12-10       Impact factor: 2.945

10.  Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trials.

Authors:  Asres Berhan; Alex Barker
Journal:  BMC Endocr Disord       Date:  2013-12-17       Impact factor: 2.763

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.